Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Pembrolizumab
Keytruda
Routinely available
SMC (SMC2767)
18/03/2026
Indication
In combination with carboplatin and paclitaxel, for the first-line treatment of primary advanced or recurrent endometrial carcinoma in adults.
Therapeutic Area
Malignant disease and immunosuppression
Status Description
Routinely available in line with national guidance
Formulation
Concentrate for solution for infusion